La Jolla Pharmaceutical Company
Save
–
Market cap
47.62x
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States.
Similar securities
Based on sector and market capitalization
Report issue